Lista de obras - Deborah L. White - Dominio Público Uruguay

A DNA real-time quantitative PCR method suitable for routine monitoring of low levels of minimal residual disease in chronic myeloid leukemia

artículo científico publicado en 2014

A Method for Next-Generation Sequencing of Paired Diagnostic and Remission Samples to Detect Mitochondrial DNA Mutations Associated with Leukemia

scientific article published on 18 July 2017

A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia.

artículo científico publicado en 2013

A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH.

artículo científico publicado en 2017

ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines

artículo científico publicado en 2016

ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells

artículo científico publicado en 2018

Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant.

artículo científico publicado en 2016

Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy

artículo científico publicado en 2012

BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia

artículo científico publicado en 2016

BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia

artículo científico publicado en 2018

BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

scientific article published in Nature

Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors

artículo científico publicado en 2010

CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.

artículo científico publicado en 2017

COBL is a novel hotspot for IKZF1 deletions in childhood acute lymphoblastic leukemia

artículo científico publicado en 2016

CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients

artículo científico publicado en 2016

Characterization of leukemias with ETV6-ABL1 fusion

artículo científico publicado en 2016

Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity

artículo científico publicado en 2010

Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib

artículo científico publicado en 2011

Clarithromycin enhances dasatinib-induced cell death in chronic myeloid leukemia cells, by inhibition of late stage autophagy

scientific article published on 09 July 2012

Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib response.

artículo científico publicado en 2012

DETECTION OF REARRANGEMENT WITHIN THE BREAKPOINT CLUSTER REGION OF CHROMOSOME 22 IN THE DIAGNOSIS OF CHRONIC MYELOID LEUKEMIA

artículo científico publicado en 1989

Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications

artículo científico publicado en 2008

Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells

artículo científico publicado en 2012

Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2.

artículo científico publicado en 2012

Detection of minimal residual disease in an AML patient with trisomy 8 using interphase FISH

artículo científico publicado en 1997

Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions

artículo científico publicado en 2017

Elevated PTPN2 expression is associated with inferior molecular response in de-novo chronic myeloid leukaemia patients

artículo científico publicado en 2013

Expression of the non-T ALL-associated p24 antigen on leukaemic blasts from patients with ANLL

artículo científico publicado en 1987

Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib

artículo científico publicado en 2010

Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib

article

Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X Ten.

artículo científico publicado en 2018

Health protection during the Ebola crisis: the Defence Medical Services approach.

artículo científico publicado en 2016

High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment

artículo científico publicado en 2017

Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs

artículo científico publicado en 2007

Imatinib trough levels in chronic myelogenous leukemia: does one dose fit all?

artículo científico publicado en 2010

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

artículo científico publicado en 2008

In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML.

artículo científico publicado en 2005

In-vitro modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene RANBP2-ABL1 - implications for targeted therapy

scientific article published on 02 January 2021

Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells

artículo científico publicado en 2017

Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib.

artículo científico

Is telomerase a player in chronic phase chronic myeloid leukemia, disease progression and imatinib resistance?

artículo científico publicado en 2008

KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy.

artículo científico publicado en 2015

KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease

scientific article published on 06 November 2019

Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia

scientific article published on 27 March 2019

Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission

scientific article published on 25 November 2019

Living with CML: is death no longer the end (point)?

artículo científico publicado en 2015

Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells

artículo científico publicado en 2018

Low GFI1 expression in white blood cells of CP-CML patients at diagnosis is strongly associated with subsequent blastic transformation

artículo científico publicado en 2013

Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia

artículo científico publicado en 2007

Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia

artículo científico publicado en 2017

Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant + cell lines

scientific article published on 05 October 2018

Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells

artículo científico publicado en 2013

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

article

NPM1 mutations occur rarely or not at all in chronic myeloid leukaemia patients in chronic phase or blast crisis

artículo científico publicado en 2012

Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells

artículo científico publicado en 2010

Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy

artículo científico publicado en 2009

OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1.

artículo científico publicado en 2010

OCT-1 as a determinant of response to antileukemic treatment.

artículo científico publicado en 2011

OCT-1 function varies with cell lineage but is not influenced by BCR-ABL.

artículo científico publicado en 2010

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

artículo científico publicado en 2006

OCT1 and imatinib transport in CML: is it clinically relevant?

artículo científico

Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients

artículo científico publicado en 2011

Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy.

artículo científico publicado en 2018

Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients?

artículo científico publicado en 2010

Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells

artículo científico publicado en 2015

Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression

artículo científico publicado en 2018

Precision medicine approaches may be the future for CRLF2 rearranged Down Syndrome Acute Lymphoblastic Leukaemia patients

Predicting the response of CML patients to tyrosine kinase inhibitor therapy

artículo científico publicado en 2009

Predicting the response of CML patients to tyrosine kinase inhibitor therapy

scientific article published on June 2011

Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells.

artículo científico publicado en 2012

Quantitative phosphotyrosine profiling of patient-derived xenografts identifies therapeutic targets in pediatric leukemia.

artículo científico publicado en 2016

Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia

artículo científico publicado en 2016

Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment.

artículo científico publicado en 2014

Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols

scientific article published on 10 October 2019

Response to 'Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?'

artículo científico publicado en 2016

SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia

artículo científico publicado en 2011

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

artículo científico publicado en 2013

Selected CD34 blood cell allografts for older patients: low transplant-related mortality, graft failure and acute GvHD

scientific article published on 01 January 2003

Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL(+) cells

artículo científico publicado en 2009

Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR.

artículo científico publicado en 2003

Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia

artículo científico publicado en 2014

TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy

artículo científico publicado en 2016

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets

artículo científico publicado en 2014

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia

artículo científico publicado en 2014

The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment

artículo científico publicado en 2016

The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALL

scientific article published on 03 December 2019

The expression of mature myeloid cell differentiation markers in acute leukemia.

artículo científico publicado en 1987

The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro.

artículo científico publicado en 2018

The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells

artículo científico publicado en 2010

Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways

artículo científico publicado en 2011

Unraveling the "known unknowns": lessons and reflections from the new directions in leukemia research 2012 conference

artículo científico publicado en 2012

Which TKI? An embarrassment of riches for chronic myeloid leukemia patients

artículo científico

Widespread Aberrant Alternative Splicing despite Molecular Remission in Chronic Myeloid Leukaemia Patients

artículo científico publicado en 2020

Xenograft-directed personalized therapy for a patient with post-transplant relapse of ALL.

artículo científico publicado en 2016

Lista de obras de Deborah L. White

A DNA real-time quantitative PCR method suitable for routine monitoring of low levels of minimal residual disease in chronic myeloid leukemia

A Method for Next-Generation Sequencing of Paired Diagnostic and Remission Samples to Detect Mitochondrial DNA Mutations Associated with Leukemia

A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia.

A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH.

ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines

ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells

Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant.

Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy

BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia

BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia

BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors

CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.

COBL is a novel hotspot for IKZF1 deletions in childhood acute lymphoblastic leukemia

CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients

Characterization of leukemias with ETV6-ABL1 fusion

Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity

Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib

Clarithromycin enhances dasatinib-induced cell death in chronic myeloid leukemia cells, by inhibition of late stage autophagy

Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib response.

DETECTION OF REARRANGEMENT WITHIN THE BREAKPOINT CLUSTER REGION OF CHROMOSOME 22 IN THE DIAGNOSIS OF CHRONIC MYELOID LEUKEMIA

Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications

Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells

Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2.

Detection of minimal residual disease in an AML patient with trisomy 8 using interphase FISH

Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions

Elevated PTPN2 expression is associated with inferior molecular response in de-novo chronic myeloid leukaemia patients

Expression of the non-T ALL-associated p24 antigen on leukaemic blasts from patients with ANLL

Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib

Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib

Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X Ten.

Health protection during the Ebola crisis: the Defence Medical Services approach.

High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment

Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs

Imatinib trough levels in chronic myelogenous leukemia: does one dose fit all?

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML.

In-vitro modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene RANBP2-ABL1 - implications for targeted therapy

Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells

Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib.

Is telomerase a player in chronic phase chronic myeloid leukemia, disease progression and imatinib resistance?

KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy.

KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease

Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia

Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission

Living with CML: is death no longer the end (point)?

Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells

Low GFI1 expression in white blood cells of CP-CML patients at diagnosis is strongly associated with subsequent blastic transformation

Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia

Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia

Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant + cell lines

Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

NPM1 mutations occur rarely or not at all in chronic myeloid leukaemia patients in chronic phase or blast crisis

Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells

Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy

OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1.

OCT-1 as a determinant of response to antileukemic treatment.

OCT-1 function varies with cell lineage but is not influenced by BCR-ABL.

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

OCT1 and imatinib transport in CML: is it clinically relevant?

Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients

Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy.

Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients?

Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells

Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression

Precision medicine approaches may be the future for CRLF2 rearranged Down Syndrome Acute Lymphoblastic Leukaemia patients

Predicting the response of CML patients to tyrosine kinase inhibitor therapy

Predicting the response of CML patients to tyrosine kinase inhibitor therapy

Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells.

Quantitative phosphotyrosine profiling of patient-derived xenografts identifies therapeutic targets in pediatric leukemia.

Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia

Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment.

Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols

Response to 'Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?'

SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

Selected CD34 blood cell allografts for older patients: low transplant-related mortality, graft failure and acute GvHD

Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL(+) cells